Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00347061 | Long Term Safety of SL77.0499-10 (Alfuzosin) in Patients With BPH | PHASE3 | COMPLETED | 148 | — | — | May 1, 2006 | Oct 1, 2007 | Oct 2, 2009 | 1 | Japan |
| Name | Type | Description |
|---|---|---|
| afuzosin | DRUG | - |
Inclusion Criteria: * Having a symptomatic BPH diagnosed clinically by digital rectal examination and ultrasonography * Suffering for at least 6 months from lower urinary tract symptoms related to BPH * An I-PSS total score ≥ 13 * Out patient Exclusion Criteria: * Patients previously treated with...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Boston Scientific Corporation | BSX | 2 | — | Undisclosed |
| PROCEPT BioRobotics Corp. | PRCT | 2 | NA | Undisclosed |
| EDAP TMS SA Sponsored ADR | EDAP | 1 | NA | Undisclosed |
| Profound Medical Corp | PROF | 1 | — | Undisclosed |